About this Research Topic
The massively increasing number of individuals affected by AD, with huge economic and social impact, explains the primary interest of research to identify early disease-modifying therapies aimed at targeting Aβ peptide in order to prevent and mitigate its neurotoxicity. Despite the enormous effort made by researchers in the last decades, the largest majority of drugs entering clinical trials has not been approved. Thus, the development of novel treatments to prevent the decline in functional activities of daily living and improve the quality of life of older adults is of fundamental importance. The goal of this Research Topic is to provide an update on new and recently proposed possible anti-Aβ therapies, including natural products, but also synthetic rationally-designed antibodies and modulators of its aggregation and neurotoxicity.
The scope of the present Research Topic is to update the readers on the most advanced therapeutic approaches targeting Aβ peptide. Original research papers, reviews, perspectives, and short communications related to the current Research Topic are warmly welcome. The areas covered by this Research Topic may include but are not limited to:
• Active and passive anti Aβ immunotherapy
• Secretases inhibitors and modulators
• Modulators of Aβ aggregation and clearance
• Modulators of signal transduction pathways activated by Aβ aggregates
Keywords: Alzheimer disease, amyloid, therapeutic targets, immunotherapy, rationally-design molecules, therapy, natural compounds, aggregation, protein-ligand interaction
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.